{"id":"ckdb-501a","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, CKDB-501A reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes. The exact molecular mechanism is not fully understood, but it is believed to involve the inhibition of SGLT2-mediated glucose transport.","oneSentence":"CKDB-501A is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:14.119Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05804656","phase":"PHASE3","title":"Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial","status":"COMPLETED","sponsor":"CKD Bio Corporation","startDate":"2023-04-13","conditions":"Glabellar Lines","enrollment":300},{"nctId":"NCT05382767","phase":"PHASE1","title":"Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity","status":"COMPLETED","sponsor":"CKD Bio Corporation","startDate":"2022-06-02","conditions":"Post-stroke Upper Limb Spasticity","enrollment":24},{"nctId":"NCT05292638","phase":"PHASE1","title":"Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines","status":"COMPLETED","sponsor":"CKD Bio Corporation","startDate":"2022-02-15","conditions":"Glabellar Lines","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CKDB-501A","genericName":"CKDB-501A","companyName":"CKD Bio Corporation","companyId":"ckd-bio-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CKDB-501A is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}